INTRODUCTION
From the advent of the antibiotic era, the empiric use of broad-spectrum antibiotics has resulted in the emergence and cross-species spread of antibiotic resistance in many opportunistic bacteria (1) . Multidrug resistance, coupled with the lack of innovative antibiotic development, threatens to send us back into a preantibiotic era (2, 3) . An increasing awareness that broad-spectrum antibiotic use disrupts the beneficial microbiome and increases the risk for multiple metabolic, inflammatory, and infectious diseases has strengthened the rationale for pathogenspecific antibacterial strategies. However, one substantial concern with any pathogen-specific antibacterial approach is that targeting a single species may not provide sufficient coverage in a polymicrobial infection.
Bacterial pneumonia is an important cause of morbidity and mortality, particularly in the hospital setting, in immunocompromised individuals and among the very young and the elderly (4, 5) . Although one infecting pathogen may apparently predominate, infection often results from initial colonization or subclinical infection with multiple pathogens (6) (7) (8) . For example, Staphylococcus aureus and Pseudomonas aeruginosa are often observed in sequence or together in the lung, and respiratory co-infections with these opportunists correlate with worse clinical outcome than mono-infection with either pathogen (9) (10) (11) (12) (13) (14) (15) . Coinfection with S. aureus and Klebsiella pneumoniae resulted in increased lung pathology relative to mono-infections (14) . Mortality rate was higher among co-infected individuals; however, this might not be solely attributable to the mixed infection because these patients also had increased rates of underlying illness such as cardiac diseases. Also, >30% of patients with ventilator-associated pneumonia (VAP) suffer from polymicrobial infections, and S. aureus is one of the most commonly cultured pathogens in polymicrobial VAP (16) . The severity of the co-infections relative to mono-infections was not clear from this study. Future clinical studies are required to determine if polymicrobial infections are associated with worse outcomes in VAP patients. Here, we investigated whether S. aureus could potentiate infection with Gram-negative bacteria and which S. aureus virulence factors are responsible for this potentiation.
Monoclonal antibody (mAb)-based approaches to prevent pneumonia by precise targeting of individual virulence factors have shown promise in the prevention and treatment of S. aureus or P. aeruginosa pneumonia in preclinical models (17) (18) (19) . We demonstrate that multiple Gram-negative organisms take advantage of the effects of S. aureus a toxin (AT) on mucosal host defense, specifically macrophage function, resulting in proliferation and dissemination of the coinfecting Gram-negative pathogens. It was noteworthy that passive immunization with anti-AT mAb, MEDI4893*, promoted clearance of both S. aureus and the co-infecting Gram-negative pathogen. These data suggest that co-infection with S. aureus expressing AT may be a risk factor for Gram-negative disease and demonstrate that pathogenspecific, antibody-based approaches for prophylaxis or therapy could be effective against mixed opportunistic infections without resorting to empiric broad-spectrum antibiotics.
RESULTS

S. aureus enhances Gram-negative bacterial proliferation and lethality
To examine the impact and growth of S. aureus and P. aeruginosa in a mixed infection, mice were coinfected intranasally with sublethal doses of S. aureus (SF8300, CC8) and P. aeruginosa (6077, ExoU was similar in the mono-and mixed-infected lungs at up to 8 hours, and by 24 hours after infection, P. aeruginosa numbers were reduced in the lungs of mono-infected mice. In contrast, striking proliferation of P. aeruginosa in the lungs of S. aureus + P. aeruginosa-co-infected mice was evident from 8 to 24 hours (P = 0.0005) and 48 hours (P < 0.0001) after infection with significantly more P. aeruginosa recovered (P < 0.0001) compared to mono-infection. Pseudomonas proliferation in the lung was accompanied by dissemination as evidenced by increased numbers of P. aeruginosa in the spleen (P = 0.018) 48 hours after infection relative to animals that had been challenged with P. aeruginosa alone (Fig. 1C and table S1 ). To investigate whether S. aureus could potentiate infection with other Gram-negative bacteria, mice were challenged intranasally with either K. pneumoniae or Acinetobacter baumannii alone or in combination with S. aureus. Although most animals survived the mono-infections, 90 to 100% lethality was observed upon co-infection coupled with increased K. pneumoniae and A. baumannii bacterial burden in the lungs and spleens of co-infected animals ( Fig. 1, D to I, and table S1). These data indicate that S. aureus can potentiate proliferation, dissemination, and disease with a range of clinically relevant Gramnegative opportunistic bacterial pathogens.
Pathogen-specific mAbs reduce co-infection disease severity
We previously demonstrated that treatment with MEDI3902, a bispecific mAb targeting P. aeruginosa, protected animals from intranasal challenge with P. aeruginosa (17) . Here, immunoprophylaxis with MEDI3902 significantly increased survival (P < 0.0001) of mice coinfected with S. aureus + P. aeruginosa and reduced both S. aureus and P. aeruginosa CFU in the lungs compared to an isotype control immunoglobulin G (c-IgG) (P = 0.0022 and P = 0.0023, respectively) (Fig. 2, A and B) . Likewise, immunoprophylaxis with MEDI4893*, a mAb targeting S. aureus AT also shown to protect mice against lethal S. aureus challenge (18, 20) , increased survival of S. aureus + P. aeruginosa-co-infected animals and reduced the lung burden of both bacteria by greater than 1 log (Fig. 2 , C and D). MEDI4893* had a similar effect when animals were infected with P. aeruginosa along with other strains of S. aureus, NRS387 (CC5) and NRS261 (CC30) ( fig. S1 ), as well as S. aureus + K. pneumoniae and S. aureus + A. baumannii mixed infections ( fig. S2 , A to D).
To assess whether pathogen-specific mAbs could treat a co-infection, MEDI4893* and MEDI3902 were administered at various times after S. aureus + P. aeruginosa infection. Whereas MEDI3902 conferred significant (P < 0.0001) protection when administered as late as 8 hours after coinfection ( Fig. 2A) , MEDI4893* afforded significant (P = 0.0105) protection only when administered up to 1 hour after infection (Fig. 2C) . These data suggest that at the onset of infection, S. aureus suppresses innate defense mechanisms, enabling the proliferation of P. aeruginosa, which ultimately results in death of the co-infected animals.
AT is sufficient for promotion of enhanced Gram-negative pneumonia The above studies suggested that AT plays a key role in the S. aureus-mediated potentiation of Gram-negative growth and dissemination during a mixed infection; however, S. aureus produces an array of virulence factors that contribute to disease pathogenesis (21) . To confirm a role for AT and identify other potential virulence factors that may promote lethality in the Fig. 1 . S. aureus promotes Gram-negative infection. (A) Survival of mice infected with S. aureus (5e7 CFU) (Sa), P. aeruginosa (1e5 CFU) (Pa), or S. aureus + P. aeruginosa. (B) S. aureus or P. aeruginosa CFU recovered from the lungs of mice infected as described above at various time points. (C) P. aeruginosa CFU recovered from the spleens of mice after infection with P. aeruginosa or S. aureus + P. aeruginosa at various time points. (D) Survival of mice infected with S. aureus (5e7 CFU), K. pneumoniae (5e1 CFU) (Kp), or S. aureus + K. pneumoniae. (E) S. aureus or K. pneumoniae CFU recovered from the lungs of mice infected as described above at various time points. (F) K. pneumoniae CFU recovered from the spleens of mice after infection with K. pneumoniae or S. aureus + K. pneumoniae at various time points. (G) Survival of mice infected with S. aureus (5e7 CFU), A. baumannii (6e5 CFU) (Ab), or S. aureus + A. baumannii. (H) S. aureus or A. baumannii CFU recovered from the lungs of mice infected as described above at various time points. (I) A. baumannii CFU recovered from the spleens of mice after infection with A. baumannii or S. aureus + A. baumannii at various time points. Significance was determined by log-rank test (A, D, and G) or analysis of variance (ANOVA) followed by Dunnett's test (B, C, E, F, H, and I). F P < 0.02, compared to mixed infection; # P < 0.0001, P. aeruginosa versus S. aureus + P. aeruginosa (P. aeruginosa) and P < 0.03, S. aureus + P. aeruginosa (P. aeruginosa) versus S. aureus + P. aeruginosa (t = 4 hours) (P. aeruginosa); and *P < 0.03 mixed infection (Gram-negative) versus Gram-negative. Data are representative of at least three independent experiments. Exact P values in table S1. mixed infection, S. aureus isogenic in-frame deletion mutants, DagrA, Dpvl, DspA, DclfA, DisdH, Dpsm a-type 1,2,3,4, Dhla, and Dhla comp:hla, were tested in the P. aeruginosa mixed infection model (Fig. 3, A and B ) (22) (23) (24) (25) (26) . P. aeruginosa co-infection with all of the S. aureus mutants except for those lacking the gene for AT (Dhla), or the virulence regulator Dagr, resulted in mortality similar to that observed with P. aeruginosa + wild-type S. aureus. Significantly fewer S. aureus (P = 0.0118) and P. aeruginosa (P < 0.0001) were recovered from the lungs of mice infected with P. aeruginosa + Dhla compared to those infected with P. aeruginosa + wild-type S. aureus (Fig. 3, C To further confirm a pivotal role for AT in co-infection potentiation, mice were challenged with either a mixture of P. aeruginosa + 0.05-mg purified AT protein or P. aeruginosa + 0.05-mg AT H35L , an AT mutant defective for pore formation. A high rate of mortality was observed in the sublethal infections only with the functional wild-type AT protein (Fig. 3 , B and C). Likewise, sublethal doses of K. pneumoniae or A. baumannii + AT resulted in high rates of mortality, whereas mixtures of K. pneumoniae and A. baumannii with AT H35L did not (fig. S3, E to H). These data indicate that active AT is necessary and sufficient for enabling P. aeruginosa, K. pneumoniae, and A. baumannii proliferation and associated mortality in this murine lung infection model.
A common criticism of murine models is that murine cells are not sensitive to all S. aureus toxins; therefore, we tested the ability of AT neutralization to protect against a mixed infection in human interleukin-3/granulocyte-macrophage colony-stimulating factor (IL-3/GM-CSF) knock-in humanized mice (27) . Immunoprophylaxis with MEDI4893* resulted in greater than 1-log reduction in the numbers of S. aureus and P. aeruginosa recovered from either the lung or spleen (Fig. 3E ). These data suggest that prophylaxis with pathogen-specific mAbs can protect against a co-infection and that neutralization of a single S. aureus virulence factor, AT, can reduce proliferation and accompanying mortality associated with multiple Gram-negative pathogens.
AT affects alveolar macrophage phagocytosis of S. aureus in vivo We first hypothesized that the mortality and Gram-negative proliferation associated with the mixed infection was due to excessive inflammation resulting from the presence of multiple pathogens. However, cytokine levels in bronchoalveolar lavage fluid (BALF) of mice 8 hours after S. aureus + P. aeruginosa infection were comparable to those observed in mice infected with S. aureus alone ( fig. S4A ). Prophylaxis with MEDI4893* did not alter lung cytokine levels with the exception of IL-1b, which was reduced. In addition, animals challenged with mixtures of P. aeruginosa + AT had elevated IL-1b lung levels compared to mice challenged with sublethal doses of P. aeruginosa alone. However, inhibition of IL-1 receptor signaling with Anakinra did not protect mice from a lethal mixed infection, suggesting that AT-mediated proliferation of Gram-negative bacteria was not caused by changes in IL-1b levels ( fig. S4B ) (28) . Histological differences were not observed between mono-and mixedinfected lungs 24 hours after infection, and epithelial barrier dysfunction could be attributed entirely to the presence of P. aeruginosa ( fig. S4 , C and D). Overall, our results did not indicate that AT drives excessive lung inflammation in this coinfection model. To better elucidate how AT alters innate immunity, we first studied its impact on S. aureus clearance in mono-infections. Both alveolar macrophages (AMs; CD11c + CD11b − ) and neutrophils (CD11c − CD11b + Ly6G + ) contribute to host clearance of S. aureus in mono-infection; depletion of either cell type resulted in greater quantities (P < 0.0001) of bacteria in the lungs (Fig.4,AandB,and fig.S5 ,AandB) (29) . Similar to previous reports, MEDI4893* prophylaxis significantly (P < 0.004) improved S. aureus clearance from the lungs of infected mice (Fig. 4C) (18) . AT neutralization did not significantly alter AM, neutrophil, or inflammatory monocyte numbers in the lungs 4 and 24 hours after infection relative to cIgG-treated mice (Fig. 4, D to F) . Expression of the regulatory markers PD-L1 or CD200R on AMs and neutrophils was unaltered by MEDI4893* prophylaxis (fig. S5, C to F). These data indicated that although macrophages and neutrophils are required for optimal host defense against S. aureus, AT does not influence the numbers of these cells in the lung nor their immunologic phenotype.
We next investigated whether AT alters phagocytosis of S. aureus in vivo. AT neutralization significantly increased S. aureus association with AM (P = 0.0039), not neutrophils, 4 hours after infection as measured by flow cytometry (Fig. 4, G and H, and fig. S6 ). A similar increase in bacterial uptake by AMs is observed in mice infected with Dhla S. aureus as compared with wild-type S. aureus ( fig. S7 ). Confocal microscopy confirmed that these bacteria were not surface-associated but internalized by AM (Fig. 4I ). An increased number of S. aureus were observed within CD11c + cells recovered from MEDI4893*-treated animals as compared to c-IgG-treated animals, confirming bacterial uptake into these phagocytic cells.
Macrophage phagocytosis of S. aureus is thought to be influenced by natural killer (NK) cells; thus, we tested the effect of AT on NK cell function in vitro. Human NK cells were exquisitely sensitive to AT-mediated lysis due to their high level of ADAM10 expression, the receptor for AT (Fig. 5, A and B) . At sublytic concentrations, AT prevented interferon-g (IFN-g) production by human NK cells in response to IL-12 stimulation (Fig. 5C) AT prevents lysosome acidification and bacterial killing via calpain activation Although neutralization of AT improves S. aureus phagocytosis by AMs in vivo, it was unclear if neutralization of AT increases bacterial killing within macrophages. Processing of S. aureus was visualized in RAW 264.7 cells or human peripheral blood monocytes (hPBMCs) (31) that were pretreated with LysoTracker to visualize acidic cellular compartments. In both murine macrophages and hPBMCs, S. aureus colocalized with LysoTracker-positive compartments in the presence of MEDI4893* but not in c-IgGtreated cells (Fig. 6A and figs. S9 and S10). Macrophages were incubated with fluorescein isothiocyanate (FITC)-labeled S. aureus, and loss of FITC signal, which correlates with acidification of the bacteria's microenvironment, was measured by flow cytometry. FITC signal intensity was significantly reduced in macrophages incubated with MEDI4893* as compared with c-IgG (P < 0.0001) or S. aureus Dhla as compared with wild-type S. aureus (P = 0.0075) (Fig. 6B) . S. aureus Dhla colocalized with LysoTracker-positive compartments in hPBMCs co-incubated with AT H35L but not AT, confirming the role of AT in altering cellular processing of S. aureus (Fig. 6C) . Clostridium septicum AT, a structurally related pore-forming toxin, causes membrane Ca 2+ fluxes and activates the Ca 2+ -dependent protease calpain that cleaves the lysosomal protein Lamp2 (31). S. aureus AT, but not AT H35L , resulted in a dose-dependent increase in calpain activation in macrophages (Fig. 6D) . Incubation of hPBMCs with a calpain inhibitor restored LysoTracker colocalization with internalized S. aureus, suggesting that AT-dependent calpain activation prevents lysosomal acidification (Fig. 6E) . Bacterial killing assays were performed to determine if AT neutralization or calpain inhibition promotes S. aureus killing by macrophages. Significantly fewer bacteria (P = 0.0177) were recovered from macrophages in the presence of MEDI4893* as compared with c-IgG, or the calpain inhibitor as compared with a DMSO control (P = 0.0026), demonstrating increased bacterial killing when either AT or calpain activation was neutralized (Fig. 6, F and G) . Killing of S. aureus by hPBMCs, not human neutrophils, was increased (P = 0.0249) in the presence of MEDI4893* (Fig. 6, H and I) . These results indicate that AT alters S. aureus uptake and killing within macrophages via calpain activation.
Altered macrophage function inhibits killing of Gram-negative pathogens
The results above indicate that AT alters S. aureus killing within macrophages, but not neutrophils, and that this effect is independent of NK cell function in vivo. To gain further insight into the role for these cells during a Gram-negative lung infection, mice lacking macrophages, neutrophils, or NK cells were infected intranasally with P. aeruginosa or K. pneumoniae. Although impaired clearance of both Gram-negative bacterial species was observed in mice lacking macrophages, P. aeruginosa but not K. pneumoniae clearance was impaired by depleting neutrophils, and K. pneumoniae but not P. aeruginosa lung burden was affected by a reduction in NK cells (Fig. 7, A to C, and fig. S11 , A to C). We used a green fluorescent protein (GFP)-P. aeruginosa strain to monitor phagocytosis of P. aeruginosa during an S. aureus + P. aeruginosa mixed infection after MEDI4893* or c-IgG prophylaxis. Similar numbers of GFP-P. aeruginosa were associated with macrophages or neutrophils in mice treated with MEDI4893* or c-IgG 4 hours after infection ( fig. S11, D and E) . However, although AT did not have an impact on P. aeruginosa phagocytosis, we found that the ability of hPBMCs to kill P. aeruginosa (P = 0.0145) or K. pneumoniae (P = 0.0004) in vitro was impaired in the presence of recombinant AT, whereas human neutrophil bactericidal function was not affected (Fig. 7, D and E, and fig. S11 , F and G). hPBMCs were exposed to GFP-P. aeruginosa alone or with S. aureus at a 10:1 (GFP-P. aeruginosa/S. aureus) ratio, and bacterial processing was observed by confocal microscopy (Fig. 7F and fig. S12 ). In cells infected with GFP-P. aeruginosa alone, bacteria colocalized with LysoTracker-positive compartments, whereas GFP-P. aeruginosa were dispersed throughout the cytoplasm in cells infected with GFP-P. aeruginosa + S. aureus. Neutralization of AT restored GFP-P. aeruginosa trafficking to LysoTracker-positive compartments in cells co-infected with GFP-P. aeruginosa + S. aureus (Fig. 7G and fig. S12 ). We next tested the effect of AT neutralization on a mixed infection in mice lacking AMs (Fig. 7H and fig. 11H ). Mortality in mice lacking AM and infected with either S. aureus + P. aeruginosa or S. aureus + K. pneumoniae was not reduced by MEDI4893*. Collectively, these data indicate that AT adversely modulates macrophage killing of Gram-positive and Gram-negative bacteria in the lung, promoting Gram-negative proliferation and enhancing lethality during infection with multiple pathogens.
DISCUSSION
Pathogen-specific approaches for preventing or treating serious bacterial infections are currently progressing through the antibacterial pipeline. Whether these approaches can work against mixed infections is a pressing question. Aspiration of bacteria from the diverse flora of the upper airway or gastrointestinal tract into the smaller airways of the lower lung can result in life-threatening bacterial pneumonias, often involving two or more bacterial species (33) (34) (35) (36) . Epidemiologic studies identified a strong correlation between S. aureus colonization in the upper airway and onset of VAP, and a transition from S. aureus to P. aeruginosa as the primary pathogens in early-to late-onset VAP (37, 38) . A similar transition is observed in cystic fibrosis patients (39) (40) (41) . This sequence of infections suggests that S. aureus colonization and co-infection may promote infection by other bacterial species. Percent killed calculated as a ratio of (innocula − recovered CFU)/innocula. Significance was determined by t test (B and E to H). Data are representative of at least three independent experiments. Scale bars, 4 mm (A, C, and E).
We describe a murine lung infection model in which S. aureus in combination with different Gram-negative bacteria results in significantly increased lethality compared to mono-infection (Fig. 8) . These studies suggest that AT can potentiate growth and dissemination of multiple Gram-negative bacterial species including those that are the most problematic with respect to antibiotic resistance. Neutralization of AT with MEDI4893* reduced S. aureus CFU, prevented outgrowth of Gram-negative pathogens, and reduced mortality in this model. The potential of a pathogen-specific approach was further highlighted by targeting proliferating P. aeruginosa with MEDI3902, which also resulted in protection without resulting in S. aureus proliferation and lethality.
Previous studies have described mechanisms through which P. aeruginosa outcompetes or interacts with the host immune system to eradicate S. aureus (10, 42, 43) . Our data describe a mechanism in which P. aeruginosa takes advantage of S. aureus AT to evade clearance by macrophages in the lung. In contrast to a lethal S. aureus monoinfection, we did not observe significant S. aureus-dependent epithelial damage during lethal mixed infection. Furthermore, AT neutralization during a mixed infection did not dampen the inflammatory cytokine response, nor did it influence phagocytosis of S. aureus or P. aeruginosa by neutrophils (18, 44) . At sublytic levels, AT inhibited endosomal/ lysosomal processing of phagocytosed bacteria in macrophages, not in neutrophils. The effect of AT correlated with their respective levels of ADAM10 expression, as we, and others, observe low ADAM10 levels on neutrophils in comparison with macrophages (44) .
AMs are the primary phagocytic cells present in the uninfected lung and are therefore the first immune cells encountered by infecting pathogens, coordinating the innate immune response to bacterial pathogens (45) (46) (47) (48) . Our data suggest that they play a substantial role in the acute response to bacterial pathogens in the airway. Others have described macrophages as protective cells in models of respiratory bacterial infection, although some studies have found that AMs can contribute to disease pathology (46, 47, (49) (50) (51) (52) (53) . NK cells have been described to contribute to host defense by regulating macrophage killing function (52, 54, 55) . Whereas AMs contributed to bacterial clearance, NK cells were only required for clearance of K. pneumoniae in our model, despite increased sensitivity (and ADAM10 expression) of NK cells to AT as compared to either neutrophils or PBMCs. Our results demonstrate that AT impairs AM clearance of both S. aureus and the co-infecting Gram-negative pathogen during a mixed lung infection.
Translation of these preclinical results to the clinical setting is limited by the use of murine models. Humans, unlike mice, are sensitive to a wider range of S. aureus toxins, which could contribute to the pathogenesis of human infection (56, 57) . Members of the leukotoxin family (HlgAB, HlgCB, LukAB, LukSF, and LukDE) and the S. aureus superantigens likely contribute to the pathogenesis of S. aureus disease in humans (58) . Phenol-soluble modulins can also enable S. aureus escape from the lysosome of nonprofessional and professional phagocytes (22) . To bridge the gap from murine models to the clinical setting, we used IL-3/GM-CSF knock-in humanized mice. These animals have a humanized immune system and murine nonhematopoietic cells and are sensitive to a wider range of S. aureus toxins as suggested by our data (Fig. 3E ) and others (59) . Neutralization of AT in the humanized mice promoted clearance of both S. aureus and P. aeruginosa. In vitro, we demonstrated that lysosomal acidification properly occurs in human monocytes during infection with bacteria lacking only AT, and neutralization of this toxin in the context of wild-type S. aureus improves bacterial killing. We are also limited by the acute nature of in vivo murine models. Modeling chronic infection in a murine model has proven difficult, and therefore, we are unable to determine how S. aureus might alter a preexisting infection. Our results suggest that S. aureus might exacerbate a preexisting infection, but clinical studies are required to demonstrate this empirically. Therefore, although targeting alternate toxins may provide additional benefit in the clinical context of mixed infections, the wide strain coverage of an anti-AT antibody such as MEDI4893* and the established importance of AT as a pivotal virulence factor of S. aureus make AT an attractive therapeutic target against S. aureus.
In conclusion, we demonstrate in a murine mixed infection model that S. aureus AT greatly potentiates expansion and rapid dissemination of different opportunistic Gram-negative bacteria. Further, a mAb targeting a key virulence factor such as AT, or a mAb targeting the proliferating Gram-negative opportunist, protected against a lethal mixed bacterial infection in this murine model. These studies indicate that pathogen-specific mAb therapies have the potential to reduce the risk of serious respiratory infections with different bacterial pathogens and hold potential to treat them in the context of a mixed infection. Clinical studies are necessary to further test this hypothesis and to better define patient populations who could benefit from alternative or adjunctive precision medicine strategies to the current broad-spectrum antibiotic treatment paradigm.
MATERIALS AND METHODS
Additional materials and methods, as well as source data for all figures (table S3), can be found in the Supplementary Materials.
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